Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390193 | 0.82 | KDM4E (0.46) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL12171156 | 0.82 | KDM4E (0.46) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL30077228 | 0.82 | KDM4E (0.46) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL12292088 | 0.82 | KDM4E (0.46) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL29664894 | 0.82 | KDM4E (0.46) | MEN1LMNAKMT2AL3MBTL1CYP1A2 | |
| SCHEMBL13781111 | 0.81 | KDM4E (0.40) | MEN1KMT2AL3MBTL1CYP1A2GAA | |
| SCHEMBL14933450 | 0.80 | MAPK1 (0.40) | TP53MEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL19844346 | 0.79 | PGR (0.41) | TP53LMNAKMT2A | |
| SCHEMBL17854687 | 0.78 | KDM4E (0.42) | MEN1LMNAKMT2AL3MBTL1KDM4E | |
| SCHEMBL17038451 | 0.78 | KDM4E (0.42) | MEN1LMNAKMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257093-B1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10249831-B2 | Electronic device containing cyclic lactams | MERCK PATENT GMBH (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180040832-A1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180040832-A1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| WO-2016128103-A1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10249831-B2 | Electronic device containing cyclic lactams | OXA1L, UROD, MRPL21 | MAT2A 4059/4885TP53 4865/4885PRKCQ 2169/4885 |
| US-20180040832-A1 | ELECTRONIC DEVICE CONTAINING CYCLIC LACTAMS | OXA1L, UROD, MRPL21 | MAT2A 4059/4885TP53 4865/4885PRKCQ 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.